Cara Therapeutic (CARA)

1.78 +0.07 (+4.39%)
Real-time Cboe USD Disclaimer

Cara Therapeutic Company Profile

Equity Type
Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).
Contact Information
107 Elm Street Stamford,06902 United States
203 406 3700
Top Executives
Philip S. Portoghese 0 0000 Member of the Scientific Advisory Board
Jeffrey L. C. Ives 70 2014 Independent Director
James C. Kauer 0 0000 Member of the Scientific Advisory Board
Graeme Milligan 0 0000 Member of the Scientific Advisory Board
Harrison M. Bains 77 2014 Independent Director
Stanley J. Watson 0 0000 Member of the Scientific Advisory Board
Susan Shiff 59 2020 Independent Director
Martin A. Vogelbaum 59 2010 Independent Chairman & Lead Independent Director
Christopher A. Posner 52 2018 President, CEO & Director
Lisa von Moltke 64 2022 Independent Director
Helen Marie Boudreau 57 2023 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.